Cytokinetics, Incorporated
(NASDAQ : CYTK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.02%358.431.2%$822.67m
AMGNAmgen Inc.
-0.42%192.001.2%$549.78m
CELGCelgene Corporation
-0.10%85.701.2%$541.81m
GILDGilead Sciences, Inc.
0.69%77.650.9%$486.04m
SRPTSarepta Therapeutics, Inc.
-0.62%134.5116.6%$345.10m
VRTXVertex Pharmaceuticals Incorporated
-0.23%180.721.9%$321.35m
REGNRegeneron Pharmaceuticals, Inc.
0.12%366.422.6%$293.85m
ILMNIllumina, Inc.
0.81%309.773.5%$269.39m
BLUEBluebird Bio, Inc.
0.06%179.6515.7%$208.27m
NKTRNektar Therapeutics
1.90%48.795.6%$178.77m
ALXNAlexion Pharmaceuticals, Inc.
-0.32%135.212.0%$175.84m
FMIFoundation Medicine, Inc.
0.09%136.938.8%$160.93m
EXASExact Sciences Corporation
0.81%67.2825.4%$160.59m
EXELExelixis, Inc.
0.05%21.346.4%$135.83m
AAgilent Technologies, Inc.
2.05%64.281.5%$132.94m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.